ArticleGastroenterology2026
Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
Article in Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between migraine and gut microbiota: a systematic review.Acta neurologica Belgica · 2025Pooled it
- Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial.Nature communications · 2026Trial
- Identification of human DP8α regulatory T cell sub-populations reactive to health-associated anti-inflammatory gut commensals.Gut microbes · 2026Article
- Short-chain fatty acid-producing commensals: Key modulators of AD neuroinflammation via the microbiota-gut-brain axis.Current research in microbial sciences · 2026Review
- Microphysiological models of human gastrointestinal diseases.Nature biomedical engineering · 2026Review
- Microbiome signatures and mechanistic pathways in pediatric obesity: from early-life risk to precision interventions.World journal of pediatrics : WJP · 2026Review
- Faecalibacterium prausnitzii-derived L-arginine ameliorates insomnia by inhibiting POMC-ACTH-cortisol axis.Cell reports. Medicine · 2026Article
- Microbiome dysbiosis in long COVID: a scoping review of mechanistic insights, symptom associations, and therapeutic targets.Gut pathogens · 2026Review
- Antibiotic-Driven Gut Microbiome Dysbiosis: Resistome Dynamics, Metabolic Disruption, and Paths to Restoration.Antibiotics (Basel, Switzerland) · 2026Review
- Gut microbiome remodeling across hepatocellular carcinoma progression and transarterial chemoembolization is associated with therapeutic response and prognosis.Clinical and experimental medicine · 2026Article
- Pulmonary injury in inflammatory bowel disease: intestinal barrier disruption, gut-lung axis remodeling, and treatment-related lung toxicity.Frontiers in immunology · 2026Review
- The role of the gut-lung axis in persistent inflammation and disease progression in chronic obstructive pulmonary disease: mechanistic evidence and therapeutic implications.Frontiers in immunology · 2026Review
- Dietary fiber as a microbiota-modulating strategy after endoscopic mucosa resection: A new frontier in postoperative care.World journal of gastrointestinal surgery · 2025Article
- Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsFaecalibacterium prausnitzii, a highly abundant gut bacterium, has been linked to overall health, and is decreased in several pathologic conditions, such as inflammatory bowel disease (IBD). F prausnitzii has shown anti-inflammatory properties in human and mouse models, notably through the induction of interleukin 10 (IL10) signaling. Here, we investigated which cell types from human blood and intestinal tissue are responsible for producing IL10 induced by F prausnitzii and provide the first mechanistic insights.
methodsImmune cells isolated from human blood and intestinal lamina propria of IBD patients and noninflamed controls, were stimulated with F prausnitzii EXL01 strain, Coprococcus comes 27758 strain, and Escherichia coli MG1655 strain, with or without lipopolysaccharide (LPS), and analyzed by LEGENDplex, enzyme-linked immunosorbent assay, flow cytometry, RNA sequencing, and Seahorse technology.
resultsF prausnitzii induced a direct and dose-dependent production of IL10 in cluster of differentiation 14
conclusionsF prausnitzii induces an anti-inflammatory response and rewires energy metabolism in human monocytes in healthy and inflamed conditions, potentially explaining its beneficial impact on intestinal inflammation and human health in general. These results provide new insight into the mechanisms underlying the anti-inflammatory effects of F prausnitzii and are crucial for a better understanding of its potential use in IBD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.